Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Notes Payables (2016 - 2018)

Viking Therapeutics (VKTX) has disclosed Notes Payables for 5 consecutive years, with $3.7 million as the latest value for Q1 2018.

  • Quarterly Notes Payables changed N/A to $3.7 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Mar 2018, changed N/A year-over-year, with the annual reading at $3.5 million for FY2017, 5.55% up from the prior year.
  • Notes Payables hit $3.7 million in Q1 2018 for Viking Therapeutics, up from $3.5 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $3.7 million in Q1 2018 to a low of $304274.0 in Q4 2014.
  • Historically, Notes Payables has averaged $2.4 million across 5 years, with a median of $2.5 million in 2015.
  • Biggest five-year swings in Notes Payables: skyrocketed 721.63% in 2015 and later grew 5.55% in 2017.
  • Year by year, Notes Payables stood at $304274.0 in 2014, then surged by 721.63% to $2.5 million in 2015, then soared by 30.78% to $3.3 million in 2016, then grew by 5.55% to $3.5 million in 2017, then grew by 7.82% to $3.7 million in 2018.
  • Business Quant data shows Notes Payables for VKTX at $3.7 million in Q1 2018, $3.5 million in Q4 2017, and $3.2 million in Q3 2017.